Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(11%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_2
3
33%
Ph phase_3
3
33%
Ph not_applicable
2
22%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Other(2)

Detailed Status

Completed6
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (37.5%)
Phase 33 (37.5%)
N/A2 (25.0%)

Trials by Status

recruiting111%
completed667%
unknown222%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

NCT05957978
recruitingnot_applicable

Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

NCT06907498
completedphase_3

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

NCT03129646
completedphase_2

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

NCT03829917
unknown

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

NCT01641796
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05957978Phase 2

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Completed
NCT06907498Not Applicable

Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

Recruiting
NCT03129646Phase 3

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Completed
NCT03829917Phase 2

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

Completed
NCT01641796

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

Unknown
NCT03399955Phase 2

Short Course Regimens for Treatment of PKDL (Sudan)

Unknown
NCT01790659Phase 3

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Completed
NCT00004444Not Applicable

Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis

Completed
NCT00629031Phase 3

An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9